LakeShore Biopharma Warrants
LSBPW
LSBPW was delisted on the 19th of September, 2025.
28 hedge funds and large institutions have $266K invested in LakeShore Biopharma Warrants in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.46% less ownership
Funds ownership: 6.36% → 5.9% (-0.46%)
7% less funds holding
Funds holding: 30 → 28 (-2)
25% less capital invested
Capital invested by funds: $356K → $266K (-$89.3K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$417 |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$40 |
| 3 |
CS
Clear Street
New York
|
+$7 |
| 4 |
CAC
Cowen and Company
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
-$11.3K |
| 2 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$2.42K |
| 3 |
ETH
Exos TFP Holdings
New York
|
-$1.62K |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$1.49K |
| 5 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$780 |
LSBPW Hedge Fund Activity: Q4 2023 in Review
28 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q4 2023, worth a combined $266K — down 25% from $356K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LSBPW and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $417. The largest seller was Ionic Capital Management, exiting entirely with an estimated $11.3K sold.
- 28 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q4 2023, down from 30 in Q3 2023.
- Funds reported $266K of LakeShore Biopharma Warrants stock for Q4 2023, down 25% quarter-over-quarter.
- 2 funds opened new LakeShore Biopharma Warrants positions in Q4 2023 and 4 closed out, a net change of -2 holders.
- The largest LakeShore Biopharma Warrants buyer in Q4 2023 was Susquehanna International Group, an estimated $417 added.
- The largest LakeShore Biopharma Warrants seller in Q4 2023 was Ionic Capital Management, an estimated $11.3K sold.
Based on aggregated 13F filings for Q4 2023.